Go to
JCI Insight
Citations to this article
Eric Salazar, … , Vivek Kapur, James M. Musser
Published September 10, 2020
Citation Information: J Clin Invest. 2020;130(12):6728-6738. https://doi.org/10.1172/JCI141206.
Citation Information: J Clin Invest. 2020;130(12):6728-6738. https://doi.org/10.1172/JCI141206.
Abstract
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied the relationship among anti-spike ectodomain (anti-ECD), anti–receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by 2 in vitro assays using convalescent plasma samples from 68 patients with COVID-19. We report a strong positive correlation between both plasma anti-RBD and anti-ECD IgG titers and in vitro VN titers. The probability of a VN titer of ≥160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment, was ≥80% when anti-RBD or anti-ECD titers were ≥1:1350. Of all donors, 37% lacked VN titers of ≥160. Dyspnea, hospitalization, and disease severity were significantly associated with higher VN titer. Frequent donation of convalescent plasma did not significantly decrease VN or IgG titers. Analysis of 2814 asymptomatic adults found 73 individuals with anti-ECD IgG titers of ≥1:50 and strong positive correlation with anti-RBD and VN titers. Fourteen of these individuals had VN titers of ≥1:160, and all of them had anti-RBD titers of ≥1:1350. We conclude that anti-RBD or anti-ECD IgG titers can serve as a surrogate for VN titers to identify suitable plasma donors. Plasma anti-RBD or anti-ECD titers of ≥1:1350 may provide critical information about protection against COVID-19 disease.
Authors
Eric Salazar, Suresh V. Kuchipudi, Paul A. Christensen, Todd Eagar, Xin Yi, Picheng Zhao, Zhicheng Jin, S. Wesley Long, Randall J. Olsen, Jian Chen, Brian Castillo, Christopher Leveque, Dalton Towers, Jason Lavinder, Jimmy Gollihar, Jose Cardona, Gregory Ippolito, Ruth Nissly, Ian Bird, Denver Greenawalt, Randall M. Rossi, Abhinay Gontu, Sreenidhi Srinivasan, Indira Poojary, Isabella M. Cattadori, Peter J. Hudson, Nicole M. Josleyn, Laura Prugar, Kathleen Huie, Andrew Herbert, David W. Bernard, John M. Dye, Vivek Kapur, James M. Musser
Citation information
Citations to this article (139)
| Title and authors | Publication | Year |
|---|---|---|
|
Neutralizing antibody levels as a key factor in determining the immunogenic efficacy of the novel PEDV alpha coronavirus vaccine
Hu G, Luo X, Liao J, Zou C, Huang Y, Geng R, Zhao Z, Shen H, Cao Y, Peng O, Zhang H |
The Veterinary Quarterly | 2025 |
|
COVID-19 Antibody Levels among Various Vaccination Groups, One-Year Antibody Follow-Up in Two University Hospitals from Western and Central Turkey.
Soylu M, Sağıroğlu P, Özarslan MA, Acet O, Yüce ZT, İzci Çetinkaya F, Durmaz S, Parkan ÖM, Akyol D, Zeytinoğlu A, Kalın Ünüvar G, Taşbakan M, Gökahmetoğlu S, Atalay MA, Durusoy İR, Çiçek C, Pullukçu H, Yıldız O, Sertöz ŞR, Erensoy MS |
Human vaccines | 2024 |
|
A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms.
Ben Hamouda W, Hanachi M, Ben Hamouda S, Kammoun Rebai W, Gharbi A, Baccouche A, Bettaieb J, Souiai O, Barbouche MR, Dellagi K, Ben Ahmed M, Benabdessalem C |
Tropical Medicine and Infectious Disease | 2024 |
|
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Park H, Yu C, Pirofski LA, Yoon H, Wu D, Li Y, Tarpey T, Petkova E, Antman EM, Troxel AB |
BMC Infectious Diseases | 2024 |
|
Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2
Connor RI, Sakharkar M, Rappazzo CG, Kaku CI, Curtis NC, Shin S, Wieland-Alter WF, Wentworth J, Mielcarz DW, Weiner JA, Ackerman ME, Walker LM, Lee J, Wright PF |
Pathogens and Immunity | 2024 |
|
Retrospective Analysis of Coronavirus SARS-CoV-2 Antibody Levels in COVID-19 Convalescent Plasma From Blood Donors
He J, Zhang Y, Dong J, Zhang W, Zhu F |
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale | 2024 |
|
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines
Bangaru S, Jackson AM, Copps J, Fernández-Quintero ML, Torres JL, Richey ST, Nogal B, Sewall LM, de la Peña AT, Rehman A, Guebre-Xabier M, Girard B, Das R, Corbett-Helaire KS, Seder RA, Graham BS, Edwards DK, Patel N, Smith G, Ward AB |
bioRxiv | 2024 |
|
The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19
Łysek-Gładysińska M, Starz M, Borowiec-Sęk A, Sufin I, Wieczorek A, Chrapek M, Zarębska-Michaluk D, Sufin P, Głuszek S, Adamus-Białek W |
Journal of inflammation research | 2023 |
|
Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study
Choi MJ, Heo JY, Seo YB, Yoon YK, Sohn JW, Noh JY, Cheong HJ, Kim WJ, Choi JY, Lee YJ, Lee HW, Kim SS, Kim B, Song JY |
Human vaccines | 2023 |
|
Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity
Choi MJ, Heo JY, Seo YB, Yoon YK, Sohn JW, Noh JY, Cheong HJ, Kim WJ, Choi JY, Kim HJ, Lee YJ, Lee HW, Kim SS, Kim B, Song JY |
Frontiers in immunology | 2023 |
|
Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study
Hamada H, Futamura M, Ito H, Yamamoto R, Yata K, Iwatani Y, Inoue H, Fukatsu N, Nagai H, Hasegawa Y |
Vaccine | 2023 |
|
RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers
Aguilar R, Li X, Crowell CS, Burrell T, Vidal M, Rubio R, Jiménez A, Hernández-Luis P, Hofmann D, Mijočević H, Jeske S, Christa C, D'Ippolito E, Lingor P, Knolle PA, Roggendorf H, Priller A, Yazici S, Carolis C, Mayor A, Schreiner P, Poppert H, Beyer H, Schambeck SE, Izquierdo L, Tortajada M, Angulo A, Soutschek E, Engel P, Garcia-Basteiro A, Busch DH, Moncunill G, Protzer U, Dobaño C, Gerhard M |
Microbiology spectrum | 2023 |
|
SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination
Dieckhaus KD, Kim MJ, Shen JB, Liang TS, Kleinberg MJ, Siedlarz KM, Banach DB, Metersky ML, Fuller RP, Mortensen EM, Liang BT |
Human vaccines | 2023 |
|
Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.
Li E, Han Q, Bi J, Wei S, Wang S, Zhang Y, Liu J, Feng N, Wang T, Wu J, Yang S, Zhao Y, Liu B, Yan F, Xia X |
Frontiers in immunology | 2023 |
|
Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh
Hossain MI, Sarker P, Raqib R, Rahman MZ, Hasan R, Svezia CK, Rahman M, Amin N |
Frontiers in immunology | 2023 |
|
Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda
Oluka GK, Namubiru P, Kato L, Ankunda V, Gombe B, Cotten M, Musenero M, Kaleebu P, Fox J, Serwanga J |
Frontiers in immunology | 2023 |
|
Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)
Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Nechaeva EA, Danilenko ED, Pyankov SA, Gudymo AS, Moiseeva AA, Onkhonova GS, Pyankov OV, Sleptsova ES, Lomakin NV, Vasilyeva VS, Tulikov MV, Gusarov VG, Pulin AA, Balalaeva MA, Erofeeva SB, Terpigorev SA, Rychkova OA, Petrov IM, Delian VY, Rafalskiy VV, Tyranovets SV, Gavrilova EV, Maksyutov RA |
Human vaccines | 2023 |
|
Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study.
Amellal H, Assaid N, Charoute H, Akarid K, Maaroufi A, Ezzikouri S, Sarih M |
PloS one | 2023 |
|
Serum antibody levels to SARS-CoV-2 receptor-binding domain (RBD) in convalescent patients and vaccinated individuals of northern Nevada
Hau D, Pflughoeft KJ, Gates-Hollingsworth MA, Kaur S, Hill HJ, Arias-Umana J, Chung CC, Smith VL, Riddle MS, Healy SA, AuCoin DP |
PloS one | 2023 |
|
Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
Ruytinx P, Vandormael P, Fraussen J, Pieters Z, Thonissen S, Hellings N, Stinissen P, Callebaut I, Penders J, Vanhove K, Kieffer D, Rummens JL, Valkenborgh T, Messiaen P, Stessel B, Mesotten D, Somers V |
Scientific Reports | 2023 |
|
Binding and neutralizing antibody responses to SARS-CoV-2 in young children exceed those in adults
Ruth A. Karron, Maria Garcia Quesada, Elizabeth A. Schappell, Stephen D. Schmidt, Maria Deloria Knoll, Marissa K. Hetrich, Vic Veguilla, Nicole A Doria-Rose, Fatimah S. Dawood |
JCI Insight | 2022 |
|
Therapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review
H Al-Hajeri, F Baroun, F Abutiban, M Al-Mutairi, Y Ali, A Alawadhi, A Albasri, A Aldei, A AlEnizi, N Alhadhood, A Al-Herz, A Alkadi, W Alkanderi, A Almathkoori, N Almutairi, S Alsayegh, A Alturki, H Bahbahani, A Dehrab, A Ghanem, E Hasan, S Hayat, K Saleh, H Tarakmeh |
Postgraduate Medicine | 2022 |
|
Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals
L Münsterkötter, M Hollstein, A Hahn, A Kröger, M Schnelle, L Erpenbeck, U Groß, H Frickmann, A Zautner |
Viruses | 2022 |
|
Innovative FO-SPR Label-free Strategy for Detecting Anti-RBD Antibodies in COVID-19 Patient Serum and Whole Blood
J Qu, K Leirs, W Maes, M Imbrechts, N Callewaert, K Lagrou, N Geukens, J Lammertyn, D Spasic |
ACS Sensors | 2022 |
|
Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients
H Wang, D Yan, Y Li, Y Gong, Y Mai, B Li, X Zhu, X Wan, L Xie, H Jiang, M Zhang, M Sun, Y Yao, Y Zhu |
Infectious Diseases of Poverty | 2022 |
|
Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial
S Jochum, I Kirste, S Hortsch, V Grunert, H Legault, U Eichenlaub, B Kashlan, R Pajon |
Frontiers in immunology | 2022 |
|
Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals
S Uprichard, A OBrien, M Evdokimova, C Rowe, C Joyce, M Hackbart, Y Cruz-Pulido, C Cohen, M Rock, J Dye, P Kuehnert, K Ricks, M Casper, L Linhart, K Anderson, L Kirk, J Maggiore, A Herbert, N Clark, G Reid, S Baker |
Viruses | 2022 |
|
Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers
N Angkasekwinai, J Sewatanon, S Niyomnaitham, S Phumiamorn, K Sukapirom, S Sapsutthipas, R Sirijatuphat, O Wittawatmongkol, S Senawong, S Mahasirimongkol, S Trisiriwanich, K Chokephaibulkit |
2022 | |
|
Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine
C Cucunawangsih, R Wijaya, N Lugito, I Suriapranata |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2022 |
|
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
K Tawinprai, T Siripongboonsitti, T Porntharukchareon, B Dechates, H Monprach, G Sornsamdang, K Wittayasak, K Soonklang, N Mahanonda |
Human Vaccines & Immunotherapeutics | 2022 |
|
Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers
N Assaid, S Arich, H Charoute, K Akarid, S Ezzikouri, A Maaroufi, M Sarih |
Human vaccines | 2022 |
|
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments
A Cortés, J Casado, F Longo, J Serrano, C Saavedra, H Velasco, A Martin, J Chamorro, D Rosero, M Fernández, M Gion, N Jáñez, A Rivas, T Gordoa, Í Delfrade, Y Lage, E Miranda, M Olmedo, P Puertas, P Gajate, J Cerrillo, E Alia, R Mateos, B Romero, M Rodríguez-Domínguez, A Vallejo, A Carrato |
European Journal of Cancer | 2022 |
|
Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents
H Blain, E Tuaillon, L Gamon, A Pisoni, S Miot, M Picot |
Journal of the American Medical Directors Association | 2022 |
|
Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern
M Salehi, H Hosseini, H Jamshidi, H Jalili, P Tabarsi, M Mohraz, H Karimi, M Lotfinia, R Aalizadeh, M Mohammadi, S Ramazi, A Abdoli |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2022 |
|
COVID-19 Vaccines: Current and Future Perspectives
L Soraci, F Lattanzio, G Soraci, M Gambuzza, C Pulvirenti, A Cozza, A Corsonello, F Luciani, G Rezza |
Human vaccines | 2022 |
|
The Effect of Convalescent Plasma in Patients With Covid-19 in Intensive Care Unit
BEREANU A, CRISAN O, CONSTANTIN AM, CAINAP S, CAINAP C, DRAGULESCU R, BEREANU R, VINTILA B, ROMAN C, SAVA M |
In vivo (Athens, Greece) | 2022 |
|
SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals
Ruggiero A, Piubelli C, Calciano L, Accordini S, Valenti MT, Carbonare LD, Siracusano G, Temperton N, Tiberti N, Longoni SS, Pizzato M, Accordini S, Fantoni T, Lopalco L, Beretta A, Bisoffi Z, Zipeto D |
EBioMedicine | 2022 |
|
Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo
Igawa G, Ai T, Yamamoto T, Ito K, Nojiri S, Saito K, Wakita M, Fukuda H, Hori S, Misawa S, Miida T, Seyama K, Takahashi K, Tabe Y, Naito T |
Scientific Reports | 2022 |
|
Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
Burnouf T, Gathof B, Bloch EM, Bazin R, de Angelis V, Patidar GK, Rastvorceva RM, Oreh A, Goel R, Rahimi-Levene N, Hindawi S, Al-Riyami AZ, So-Osman C |
Transfusion Medicine Reviews | 2022 |
|
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines
Adjobimey T, Meyer J, Sollberg L, Bawolt M, Berens C, Kovačević P, Trudić A, Parcina M, Hoerauf A |
Frontiers in immunology | 2022 |
|
Development and Validation of Indirect Enzyme-Linked Immunosorbent Assays for Detecting Antibodies to SARS-CoV-2 in Cattle, Swine, and Chicken
Gontu A, Marlin EA, Ramasamy S, Neerukonda S, Anil G, Morgan J, Quraishi M, Chen C, Boorla VS, Nissly RH, Jakka P, Chothe SK, Ravichandran A, Kodali N, Amirthalingam S, LaBella L, Kelly K, Natesan P, Minns AM, Rossi RM, Werner JR, Hovingh E, Lindner SE, Tewari D, Kapur V, Vandegrift KJ, Maranas CD, Surendran Nair M, Kuchipudi SV |
Viruses | 2022 |
|
Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine
Short KK, Lathrop SK, Davison CJ, Partlow HA, Kaiser JA, Tee RD, Lorentz EB, Evans JT, Burkhart DJ |
Pharmaceutics | 2022 |
|
110例儿童奥密克戎变异株感染恢复期血清IgG抗体变化
|
2022 | |
|
COVID-19 and plasma cells: Is there long-lived protection?
Nguyen DC, Lamothe PA, Woodruff MC, Saini AS, Faliti CE, Sanz I, Lee FE |
Immunological Reviews | 2022 |
|
The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination
Forgacs D, Silva-Moraes V, Sautto GA, Hanley HB, Gattiker JL, Jefferson AM, Kolhe R, Ross TM |
Human vaccines | 2022 |
|
Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months
Eyran T, Vaisman-Mentesh A, Taussig D, Dror Y, Aizik L, Kigel A, Rosenstein S, Bahar Y, Ini D, Tur-Kaspa R, Kournos T, Marcoviciu D, Dicker D, Wine Y |
PLoS pathogens | 2022 |
|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins using chemiluminescence immunoassay and its correlation with neutralizing antibodies
Gaber Y, Abdel Alem S, Musa S, Amer K, Elnagdy T, Hassan WA, Abdelrahman RZ, Gad A, Ali MA, Badary HA, Shawky S, Talaat H, Kassem AM, Fouad R |
Virus Research | 2022 |
|
Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology
Jeremiah SS, Miyakawa K, Ryo A |
Journal of Molecular Cell Biology | 2022 |
|
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
Karger AB, Brien JD, Christen JM, Dhakal S, Kemp TJ, Klein SL, Pinto LA, Premkumar L, Roback JD, Binder RA, Boehme KW, Boppana S, Cordon-Cardo C, Crawford JM, Daiss JL, Dupuis AP II, Espino AM, Firpo-Betancourt A, Forconi C, Forrest JC, Girardin RC, Granger DA, Granger SW, Haddad NS, Heaney CD, Hunt DT, Kennedy JL, King CL, Krammer F, Kruczynski K, LaBaer J, Lee FE, Lee WT, Liu SL, Lozanski G, Lucas T, Mendu DR, Moormann AM, Murugan V, Okoye NC, Pantoja P, Payne AF, Park J, Pinninti S, Pinto AK, Pisanic N, Qiu J, Sariol CA, Simon V, Song L, Steffen TL, Stone ET, Styer LM, Suthar MS, Thomas SN, Thyagarajan B, Wajnberg A, Yates JL, Sobhani K |
mSphere | 2022 |
|
Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds
Larkey NE, Ewaisha R, Lasho MA, Roforth MM, Granger D, Jerde CR, Wu L, Gorsh A, Klassen SA, Senefeld JW, Joyner MJ, Baumann NA, Theel ES, Mills JR |
Microbiology spectrum | 2022 |
|
Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India
Misra P, Kant S, Guleria R, Rai SK, Jaiswal A, Mandal S, Medigeshi GR, Ahmad M, Rahman A, Sangral M, Yadav K, Bairwa M, Haldar P, Kumar P |
Human vaccines | 2022 |
|
Cohort profile: Stop the Spread Ottawa (SSO)—a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination
Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, Nakka K, Shir-Mohammadi K, St-Denis-Bissonnette F, Tamblyn L, Vranjkovic A, Wood LC, Booth R, Buchan CA, Crawley AM, Little J, McGuinty M, Saginur R, Langlois MA, Cooper CL |
BMJ Open | 2022 |
|
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A |
Clinical microbiology reviews | 2022 |
|
Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature
Whang SN, Shah VD, Pu L, Sheth P, Lucas GN, Lee J, Lee M, Lacy C, Duerksen-Hughes PJ, Filippov V, Lee DJ, Veltman J, Maken K, Reeves ME, Stevens WT, Herrmann P, Cao H, Lau E |
Pathogens | 2022 |
|
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects
de Boer J, Saade U, Granjon E, Trouillet-Assant S, Saade C, Pottel H, Zrein M |
PloS one | 2022 |
|
Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.
Kirste I, Hortsch S, Grunert VP, Legault H, Maglinao M, Eichenlaub U, Kashlan B, Pajon R, Jochum S |
Infectious Diseases and Therapy | 2022 |
|
Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Belem WF, Liu CH, Hu YT, Burnouf T, Lin LT |
Viruses | 2022 |
|
Determining the SARS-CoV-2 Anti-Spike Cutoff Level Denoting Neutralizing Activity Using Two Commercial Kits.
El-Ghitany EM, Hashish MH, Farghaly AG, Omran EA |
Human vaccines | 2022 |
|
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
Goldwater MS, Stampfer SD, Sean Regidor B, Bujarski S, Jew S, Chen H, Xu N, Kim C, Kim S, Berenson JR |
2022 | |
|
Adaptation-proof SARS-CoV-2 vaccine design.
Vishweshwaraiah YL, Hnath B, Rackley B, Wang J, Gontu A, Chandler M, Afonin KA, Kuchipudi SV, Christensen N, Yennawar NH, Dokholyan NV |
Advanced Functional Materials | 2022 |
|
Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study
Petrović V, Vuković V, Patić A, Marković M, Ristić M |
Human vaccines | 2022 |
|
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.
Karger AB, Brien JD, Christen JM, Dhakal S, Kemp TJ, Klein SL, Pinto LA, Premkumar L, Roback JD, Binder RA, Boehme KW, Boppana S, Cordon-Cardo C, Crawford JM, Daiss JL, Dupuis AP 2nd, Espino AM, Firpo-Betancourt A, Forconi C, Forrest JC, Girardin RC, Granger DA, Granger SW, Haddad NS, Heaney CD, Hunt DT, Kennedy JL, King CL, Krammer F, Kruczynski K, LaBaer J, Lee FE, Lee WT, Liu SL, Lozanski G, Lucas T, Mendu DR, Moormann AM, Murugan V, Okoye NC, Pantoja P, Payne AF, Park J, Pinninti S, Pinto AK, Pisanic N, Qiu J, Sariol CA, Simon V, Song L, Steffen TL, Stone ET, Styer LM, Suthar MS, Thomas SN, Thyagarajan B, Wajnberg A, Yates JL, Sobhani K |
medRxiv : the preprint server for health sciences | 2022 |
|
The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination
Forgacs D, Moraes VS, Hanley HB, Gattiker JL, Jefferson AM, Ross TM |
2022 | |
|
Epitope-specific antibody responses differentiate COVID-19 outcome and variants of concern
Courtney Voss, Sally Esmail, Xuguang Liu, Michael J Knauer, Suzanne Ackloo, Tomonori Kaneko, Lori E Lowes, Peter J Stogios, Almagul Seitova, Ashley Hutchinson, Farhad Yusifov, Tatiana Skarina, Elena Evdokimova, Peter Loppnau, Pegah Ghiabi, Taraneh Hajian, Shanshan Zhong, Husam Abdoh, Benjamin D Hedley, Vipin Bhayana, Claudio M Martin, Marat Slessarev, Benjamin Chin-Yee, Douglas D. Fraser, Ian Chin-Yee, Shawn Li |
JCI Insight | 2021 |
|
Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma
RC Girardin, AP Dupuis, AF Payne, TJ Sullivan, D Strauss, MM Parker, KA McDonough |
The Journal of Infectious Diseases | 2021 |
|
sMAdCAM: IL-6 Ratio Influences Disease Progression and Anti-Viral Responses in SARS-CoV-2 Infection
D Jagtap, VM Bhor, S Bhowmick, N Kasarpalkar, P Sagvekar, B Kulkarni, M Pathak, N Chatterjee, P Dolas, H Palav, S Kaginkar, S Bhagat, I Munshi, S Parikh, S Agrawal, C Pawar, M Kaneria, SD Mahale, J Shastri, V Patel |
Frontiers in immunology | 2021 |
|
COVID-19 convalescent plasma composition and immunological effects in severe patients
Y Acosta-Ampudia, DM Monsalve, M Rojas, Y Rodríguez, JE Gallo, JC Salazar-Uribe, MJ Santander, MP Cala, W Zapata, MI Zapata, R Manrique, JM Pardo-Oviedo, B Camacho, C Ramírez-Santana, JM Anaya |
Journal of Autoimmunity | 2021 |
|
COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
J García-Arriaza, U Garaigorta, P Pérez, A Lázaro-Frías, C Zamora, P Gastaminza, C del Fresno, JM Casasnovas, CÓ Sorzano, D Sancho, M Esteban, MT Heise |
Journal of virology | 2021 |
|
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
AO Hassan, F Feldmann, H Zhao, DT Curiel, A Okumura, TL Tang-Huau, JB Case, K Meade-White, J Callison, RE Chen, J Lovaglio, PW Hanley, DP Scott, DH Fremont, H Feldmann, MS Diamond |
Cell reports. Medicine | 2021 |
|
Effect of time and titer in convalescent plasma therapy for COVID-19
P de Candia, F Prattichizzo, S Garavelli, RL Grotta, AD Rosa, A Pontarelli, R Parrella, A Ceriello, G Matarese |
iScience | 2021 |
|
Regulatory challenges of convalescent plasma collection during the evolving stages of COVID ‐19 pandemic in the United States
S Hassan, KA West, K ConryCantilena, VD Giorgi |
Transfusion | 2021 |
|
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
MJ Joyner, RE Carter, JW Senefeld, SA Klassen, JR Mills, PW Johnson, ES Theel, CC Wiggins, KA Bruno, AM Klompas, ER Lesser, KL Kunze, MA Sexton, JC Soto, SE Baker, JR Shepherd, N van Helmond, NC Verdun, P Marks, CM van Buskirk, JL Winters, JR Stubbs, RF Rea, DO Hodge, V Herasevich, ER Whelan, AJ Clayburn, KF Larson, JG Ripoll, KJ Andersen, MR Buras, MN Vogt, JJ Dennis, RJ Regimbal, PR Bauer, JE Blair, NS Paneth, DL Fairweather, RS Wright, A Casadevall |
New England Journal of Medicine | 2021 |
|
Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case–control study
MN Klein, EW Wang, P Zimand, H Beauchamp, C Donis, MD Ward, A Martinez-Hernandez, A Tabatabai, JW Baddley, EM Bloch, KE Mullins, MJ Fontaine |
Journal of clinical pathology | 2021 |
|
Passive Immunity Should and Will Work for COVID-19 for Some Patients:
N Cimolai |
2021 | |
|
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
M Steenhuis, G Mierlo, NI Derksen, PO Heer, S Kruithof, FL Loeff, LC Berkhout, F Linty, C Reusken, J Reimerink, B Hogema, H Zaaijer, L Watering, F Swaneveld, MJ Gils, BJ Bosch, SM Ham, A Brinke, G Vidarsson, EC Schoot, T Rispens |
IBMS BoneKEy | 2021 |
|
COVID ‐19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes
AP Yokoyama, S Wendel, C BonetBub, RM Fachini, AP Dametto, F Blumm, VF Dutra, GT Candelaria, AM Sakashita, RR Machado, R FontãoWendel, N Hamerschlak, R Achkar, MS Assunção, P Scuracchio, V Nudelman, L Pastore, JR Pinho, MD Ben, RK Filho, AR Marra, MT Amano, EG Kallás, AS Helito, CR Carvalho, DB Araujo, EL Durigon, AA Camargo, LV Rizzo, LF Reis, JM Kutner |
Transfusion | 2021 |
|
Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2
SN Neerukonda, R Vassell, R Herrup, S Liu, T Wang, K Takeda, Y Yang, TL Lin, W Wang, CD Weiss, NJ Mantis |
PloS one | 2021 |
|
Selecting COVID ‐19 convalescent plasma for neutralizing antibody potency using a high‐capacity SARS‐CoV ‐2 antibody assay
EG Meyer, G Simmons, E Grebe, M Gannett, S Franz, O Darst, CD Germanio, M Stone, P Contestable, A Prichard, R Reik, R Vassallo, P Young, MP Busch, P Williamson, LJ Dumont |
Transfusion | 2021 |
|
Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG
KA Eberhardt, F Dewald, E Heger, L Gieselmann, K Vanshylla, M Wirtz, F Kleipass, W Johannis, P Schommers, H Gruell, KA Brensing, RU Müller, M Augustin, C Lehmann, M Koch, F Klein, VD Cristanziano |
Microorganisms | 2021 |
|
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
AJ Markmann, N Giallourou, DR Bhowmik, YJ Hou, A Lerner, DR Martinez, L Premkumar, H Root, D van Duin, S Napravnik, SD Graham, Q Guerra, R Raut, CJ Petropoulos, T Wrin, C Cornaby, J Schmitz, JA Kuruc, S Weiss, Y Park, R Baric, AM de Silva, DM Margolis, LA Bartelt, MF Pasetti |
mSphere | 2021 |
|
SARS-CoV-2 Antibody Testing: Where Are We Now?
E Smerczak |
Laboratory Medicine | 2021 |
|
Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
A Gontu, S Srinivasan, E Salazar, MS Nair, RH Nissly, D Greenawalt, IM Bird, CM Herzog, MJ Ferrari, I Poojary, R Katani, SE Lindner, AM Minns, R Rossi, PA Christensen, B Castillo, J Chen, TN Eagar, X Yi, P Zhao, C Leveque, RJ Olsen, DW Bernard, J Gollihar, SV Kuchipudi, JM Musser, V Kapur |
2021 | |
|
Evaluation of antibody response after COVID‐19 vaccination of healthcare workers
EB Uysal, S Gümüş, B Bektöre, H Bozkurt, A Gözalan |
Journal of Medical Virology | 2021 |
|
Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2
MF Amjadi, SE OConnell, T Armbrust, AM Mergaert, SR Narpala, PJ Halfmann, SJ Bashar, CR Glover, AS Heffron, A Taylor, B Flach, DH OConnor, Y Kawaoka, AB McDermott, AK Sethi, MA Shelef |
ImmunoHorizons | 2021 |
|
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients
N Ruetalo, R Businger, K Althaus, S Fink, F Ruoff, M Pogoda, A Iftner, T Ganzenmüller, K Hamprecht, B Flehmig, T Bakchoul, MF Templin, M Schindler, HF Rosenberg |
mSphere | 2021 |
|
Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion
OF Wirz, K Röltgen, BA Stevens, S Pandey, MK Sahoo, L Tolentino, M Verghese, K Nguyen, M Hunter, TT Snow, AR Singh, CA Blish, JR Cochran, JL Zehnder, KC Nadeau, BA Pinsky, TD Pham, SD Boyd |
Frontiers in immunology | 2021 |
|
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
S Schlickeiser, T Schwarz, S Steiner, K Wittke, NA Besher, O Meyer, U Kalus, A Pruß, F Kurth, T Zoller, M Witzenrath, LE Sander, MA Müller, C Scheibenbogen, HD Volk, C Drosten, VM Corman, LG Hanitsch |
Frontiers in immunology | 2021 |
|
Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19
RJ Malek, CA Bill, CM Vines |
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie | 2021 |
|
A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels
J Alves, L Engel, R de Vasconcelos Cabral, EL Rodrigues, L de Jesus Ribeiro, LM Higa, O da Costa Ferreira Júnior, TM Castiñeiras, I de Carvalho Leitão, A Tanuri, SA Goueli, H Zegzouti |
Scientific Reports | 2021 |
|
Human IgG and IgA responses to COVID-19 mRNA vaccines
AV Wisnewski, JC Luna, CA Redlich, AA Ansari |
PloS one | 2021 |
|
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
S Karuna, SS Li, S Grant, SR Walsh, I Frank, M Casapia, M Trahey, O Hyrien, L Fisher, MD Miner, AK Randhawa, L Polakowski, JG Kublin, L Corey, D Montefiori, JG Beeson |
PLoS Medicine | 2021 |
|
Presence and short‐term persistence of SARS‐CoV ‐2 neutralizing antibodies in COVID ‐19 convalescent plasma donors
K Annen, TE Morrison, MG DomBourian, MK McCarthy, L Huey, PA Merkel, G Andersen, E Schwartz, V Knight |
Transfusion | 2021 |
|
SARS-CoV-2 Specific IgG Antibodies Persist Over a 12-Month Period in Oral Mucosal Fluid Collected From Previously Infected Individuals
P Chellamuthu, AN Angel, MA MacMullan, N Denny, A Mades, M Santacruz, R Lopez, C Bagos, JG Casian, K Trettner, L Lopez, N Nirema, M Brobeck, N Kojima, JD Klausner, F Turner, V Slepnev, A Ibrayeva |
Frontiers in immunology | 2021 |
|
COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision
DS Segundo, A Comins-Boo, P Lamadrid-Perojo, J Irure-Ventura, JM Castillo-Otí, R Wallman, J Calvo-Montes, JM Méndez-Legaza, C Baamonde-Calzada, I Sánchez-Molina, M Lecue-Martínez, S Ventisca-Pérez, A Batlle-López, ML Hoyos |
Human vaccines | 2021 |
|
Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations
D Buratto, A Saxena, Q Ji, G Yang, S Pantano, F Zonta |
Frontiers in immunology | 2021 |
|
Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice
MT Mabrouk, K Chiem, E Rujas, WC Huang, D Jahagirdar, B Quinn, MS Nair, RH Nissly, VS Cavener, NR Boyle, TA Sornberger, SV Kuchipudi, J Ortega, JP Julien, L Martinez-Sobrido, J Lovell |
Science Advances | 2021 |
|
Clinical Evaluation of Siemens SARS-CoV-2 Total Antibody assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area
G Igawa, T Yamamoto, Y Baba, K Shinozuka, M Yuri, M Wakita, S Misawa, T Miida, T Ai, Y Tabe |
Heliyon | 2021 |
|
Elevated Humoral Immune Response to SARS-CoV-2 at High Altitudes Revealed by an Anti-RBD “In-House” ELISA
RH Tomas-Grau, D Ploper, CL Ávila, EV Pingitore, CM Galdeano, S Chaves, SB Socias, A Stagnetto, SA Navarro, RE Chahla, MA López, CJ Llapur, P Aznar, ME Alcorta, D Costas, I Flores, D Heinze, G Apfelbaum, R Mostoslavsky, G Mostoslavsky, SI Cazorla, G del Valle Perdigón, R Chehín |
Frontiers in Medicine | 2021 |
|
Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses
R Kumar, ND Christensen, RJ Maldonado, MC Bewley, A Ostman, M Sudol, EC Chen, NW Buchkovich, A Gontu, MS Nair, RH Nissly, AM Minns, V Kapur, R Rossi, SV Kuchipudi, SE Lindner, LJ Parent, JM Flanagan, NJ Buchkovich |
Viruses | 2021 |
|
Electrochemical Capillary-Flow Immunoassay for Detecting Anti-SARS-CoV-2 Nucleocapsid Protein Antibodies at the Point of Care
IC Samper, A Sánchez-Cano, W Khamcharoen, I Jang, W Siangproh, E Baldrich, BJ Geiss, DS Dandy, CS Henry |
ACS Sensors | 2021 |
|
Surrogate test performance for SARS‐CoV ‐2 neutralizing antibodies ( nAbs ) for convalescent plasma ( CCP ): How useful could they be?
S Wendel, R Fachini, RC FontãoWendel, R Mello, CV Velasquez, RR Machado, MA Brito, M Amaral, CP Soares, R Achkar, P Scuracchio, SC Miyaji, MS Erdens, EL Durigon |
Transfusion | 2021 |
|
Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report
O Lijeskić, I Klun, MS Djaković, N Gligorić, T Štajner, J Srbljanović, O Djurković-Djaković |
Human vaccines | 2021 |
|
Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
PM Maharjan, S Choe |
Human vaccines | 2021 |
|
Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti–SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer
CW Chan, X Yi, M Lenza, AD Baldwin, J Jakalski, V Tesic, KT Yeo |
American Journal of Clinical Pathology | 2021 |
|
Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics
JJ Jacob, GJ Fletcher, TM Priya, B Veeraraghavan, A Mutreja |
Indian Journal of Medical Microbiology | 2021 |
|
Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
L Li, Y Honda-Okubo, Y Huang, H Jang, MA Carlock, J Baldwin, S Piplani, AG Bebin-Blackwell, D Forgacs, K Sakamoto, A Stella, S Turville, T Chataway, A Colella, J Triccas, TM Ross, N Petrovsky |
Vaccine | 2021 |
|
An Appraisal of the Current Scenario in Vaccine Research for COVID-19
WC Chong, DK Chellappan, SD Shukla, GM Peterson, RP Patel, NK Jha, RD Eri, K Dua, MM Tambuwala, MD Shastri |
Viruses | 2021 |
|
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
SD Stampfer, MS Goldwater, S Jew, S Bujarski, B Regidor, D Daniely, H Chen, N Xu, M Li, T Green, E Fung, E Aquino, R Swift, S Eshaghian, K Preugschat, AJ Feinstein, TM Spektor, JR Berenson |
Leukemia | 2021 |
|
Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study
H Blain, E Tuaillon, L Gamon, A Pisoni, S Miot, Y Rolland, MC Picot, J Bousquet |
Allergy | 2021 |
|
Neutralizing Aptamers Block S/RBD‐ACE2 Interactions and Prevent Host Cell Infection
X Liu, Y Wang, J Wu, J Qi, Z Zeng, Q Wan, Z Chen, P Manandhar, VS Cavener, NR Boyle, X Fu, E Salazar, SV Kuchipudi, V Kapur, X Zhang, M Umetani, M Sen, RC Willson, S Chen, Y Zu |
Angewandte Chemie | 2021 |
|
SARS‐CoV ‐2 antibody persistence in COVID ‐19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance
CD Germanio, G Simmons, K Kelly, R Martinelli, O Darst, M Azimpouran, M Stone, K Hazegh, E Grebe, S Zhang, P Ma, M Orzechowski, JE Gomez, J Livny, DT Hung, R Vassallo, MP Busch, LJ Dumont |
Transfusion | 2021 |
|
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
D Hagin, T Freund, M Navon, T Halperin, D Adir, R Marom, I Levi, S Benor, Y Alcalay, NT Freund |
Journal of Allergy and Clinical Immunology | 2021 |
|
Review of Current COVID-19 Diagnostics and Opportunities for Further Development
Y Mardian, H Kosasih, M Karyana, A Neal, CY Lau |
Frontiers in Medicine | 2021 |
|
Performance study of a sterilization box using a combination of heat and ultraviolet light irradiation for the prevention of COVID-19
N Mahanta, V Saxena, LM Pandey, P Batra, US Dixit |
Environmental Research | 2021 |
|
COVID-19 serological survey using micro blood sampling
MM Matthews, TG Kim, S Shibata, N Shibata, C Butcher, J Hyun, KY Kim, T Robb, SS Jheng, M Narita, T Mori, M Collins, M Wolf |
Scientific Reports | 2021 |
|
Feasibility of convalescent plasma therapy in severe COVID‐19 patients with persistent SARS‐CoV‐2 viremia
F Camou, C Tinevez, M BeguetYachine, P Bellecave, D Ratiarison, C Tumiotto, X Lafarge, O Guisset, G Mourissoux, ME Lafon, F Bonnet, N Issa |
Journal of Medical Virology | 2021 |
|
COVID‐19 convalescent plasma therapy: hit fast, hit hard!
D Focosi, M Franchini |
Vox Sanguinis | 2021 |
|
Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern
SW Long, RJ Olsen, PA Christensen, S Subedi, R Olson, JJ Davis, MO Saavedra, P Yerramilli, L Pruitt, K Reppond, MN Shyer, J Cambric, IJ Finkelstein, J Gollihar, JM Musser |
The American Journal of Pathology | 2021 |
|
Neutralizing Aptamers Block S/RBD‐ACE2 Interactions and Prevent Host Cell Infection
X Liu, Y Wang, J Wu, J Qi, Z Zeng, Q Wan, Z Chen, P Manandhar, VS Cavener, NR Boyle, X Fu, E Salazar, SV Kuchipudi, V Kapur, X Zhang, M Umetani, M Sen, RC Willson, S Chen, Y Zu |
Angewandte Chemie (International ed. in English) | 2021 |
|
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
MS Piepenbrink, JG Park, FS Oladunni, A Deshpande, M Basu, S Sarkar, A Loos, J Woo, P Lovalenti, D Sloan, C Ye, K Chiem, CW Bates, RE Burch, NB Erdmann, PA Goepfert, VL Truong, MR Walter, L Martinez-Sobrido, JJ Kobie |
Cell reports. Medicine | 2021 |
|
SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
Y Yang, L Du |
Signal Transduction and Targeted Therapy | 2021 |
|
Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG
E Salazar, PA Christensen, EA Graviss, DT Nguyen, B Castillo, J Chen, BV Lopez, TN Eagar, X Yi, P Zhao, J Rogers, A Shehabeldin, D Joseph, F Masud, C Leveque, RJ Olsen, DW Bernard, J Gollihar, JM Musser |
The American Journal of Pathology | 2021 |
|
Serum pooling for rapid expansion of anti-SARS-CoV-2 antibody testing capacity
JW Allen, H Verkerke, J Owens, B Saeedi, D Boyer, S Shin, JD Roback, AS Neish, SR Stowell |
Transfusion Clinique et Biologique | 2021 |
|
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients
C Danthu, S Hantz, A Dahlem, M Duval, B Ba, M Guibbert, Z Ouafi, S Ponsard, I Berrahal, J Achard, F Bocquentin, V Allot, J Rerolle, S Alain, F Touré |
Journal of the American Society of Nephrology : JASN | 2021 |
|
Performance Characteristics of the Vidas SARS-CoV-2 IgM and IgG Serological Assays
N Renard, S Daniel, N Cayet, M Pecquet, F Raymond, S Pons, J Lupo, C Tourneur, C Pretis, G Gerez, P Blasco, M Combe, I Canova, M Lesénéchal, F Berthier, YW Tang |
Journal of clinical microbiology | 2021 |
|
Advances in Neutralization Assays for SARS‐CoV‐2
Lu Y, Wang J, Li Q, Hu H, Lu J, Chen Z |
Scandinavian Journal of Immunology | 2021 |
|
Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients
Dwyer CJ, Cloud CA, Wang C, Heidt P, Chakraborty P, Duke TF, McGue S, Jeffcoat B, Dunne J, Johnson L, Choi S, Nahhas GJ, Gandy AS, Babic N, Nolte FS, Howe P, Ogretmen B, Gangaraju VK, Tomlinson S, Madden B, Bridges T, Flume PA, Wrangle J, Rubinstein MP, Baliga PK, Nadig SN, Mehrotra S |
iScience | 2021 |
|
Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial
Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B, Pajon R |
2021 | |
|
What are protective antibody responses to pandemic SARS-CoV-2?
Jeffrey P. Henderson |
Journal of Clinical Investigation | 2020 |
|
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
L Lu, H Zhang, M Zhan, J Jiang, H Yin, DJ Dauphars, SY Li, Y Li, YW He |
Science China Life Sciences | 2020 |
|
SARS‐CoV‐2 neutralization and serology testing of COVID‐19 convalescent plasma from donors with nonsevere disease
TJ Gniadek, JM Thiede, WE Matchett, AR Gress, KA Pape, JK Fiege, MK Jenkins, VD Menachery, RA Langlois, TD Bold |
Transfusion | 2020 |
|
Convalescent Plasma Therapy for COVID-19: State of the Art
D Focosi, AO Anderson, JW Tang, M Tuccori |
Clinical microbiology reviews | 2020 |
|
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
KH Crawford, AS Dingens, R Eguia, CR Wolf, N Wilcox, JK Logue, K Shuey, AM Casto, B Fiala, S Wrenn, D Pettie, NP King, AL Greninger, HY Chu, JD Bloom |
The Journal of Infectious Diseases | 2020 |
|
Virus‐Free and Live‐Cell Visualizing SARS‐CoV‐2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors
Y Zhang, S Wang, Y Wu, W Hou, L Yuan, C Shen, J Wang, J Ye, Q Zheng, J Ma, J Xu, M Wei, Z Li, S Nian, H Xiong, L Zhang, Y Shi, B Fu, J Cao, C Yang, Z Li, T Yang, L Liu, H Yu, J Hu, S Ge, Y Chen, T Zhang, J Zhang, T Cheng, Q Yuan, N Xia |
Small Methods | 2020 |
|
Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
SW Long, RJ Olsen, PA Christensen, DW Bernard, JJ Davis, M Shukla, M Nguyen, MO Saavedra, P Yerramilli, L Pruitt, S Subedi, HC Kuo, H Hendrickson, G Eskandari, HA Nguyen, JH Long, M Kumaraswami, J Goike, D Boutz, J Gollihar, JS McLellan, CW Chou, K Javanmardi, IJ Finkelstein, JM Musser, RA Bonomo |
mBio | 2020 |
|
SARS‐CoV‐2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination
WC Huang, S Zhou, X He, K Chiem, MT Mabrouk, RH Nissly, IM Bird, M Strauss, S Sambhara, J Ortega, EA Wohlfert, L MartinezSobrido, SV Kuchipudi, BA Davidson, JF Lovell |
Advanced materials (Deerfield Beach, Fla.) | 2020 |
|
Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2
Johnson M, Wagstaffe HR, Gilmour KC, Mai AL, Lewis J, Hunt A, Sirr J, Bengt C, Grandjean L, Goldblatt D |
Journal of Clinical Virology | 2020 |
|
Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M, Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G, Nguyen HA, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS, Chou CW, Javanmardi K, Finkelstein IJ, Musser JM |
2020 | |
|
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang ML, Jerome KR, Bloom JD, Greninger AL |
Journal of clinical microbiology | 2020 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)